The present study revealed that coadministration with pimecrolimus hindered the therapeutic effects of hUCB-MSCs on AD by inhibiting COX2 expression via the NFAT-COX2-PGE2 axis. The gene discussed is PTGS2; the disease is Alzheimer disease.